Knight Therapeutics Enhances Collaboration with Helsinn for Onicit®
Expansion of Knight Therapeutics and Helsinn Partnership
MONTREAL and LUGANO, Switzerland – Knight Therapeutics Inc. (TSX: GUD), a pan-American specialty pharmaceutical company, has taken significant steps to enhance its partnership with Helsinn Healthcare SA, a well-respected global pharmaceutical company. This collaboration will focus on an exclusive license, distribution, and supply agreement for ONICIT® IV (palonosetron) in various Latin American markets including Mexico and Brazil. This agreement marks an exciting growth opportunity for both companies.
About the New Agreement for ONICIT®
With this new agreement, Knight Therapeutics will gain the exclusive rights to distribute, promote, market, and sell ONICIT® in the designated territories. This means that Knight will be responsible for expanding the availability of this important medication following a transition phase from Helsinn’s prior licensee. Previously, Knight and Helsinn had joined forces for the distribution of significant oncology-related products in Canada and Latin America, including AKYNZEO®.
Benefits and Strategic Importance of ONICIT®
ONICIT® serves a crucial role in the oncology space as a second-generation 5-HT3 receptor antagonist, indicating its high efficacy in managing chemotherapy-induced nausea and vomiting. A single dose of ONICIT® can provide extensive protection against these side effects over several days, which simplifies the treatment regimen for patients undergoing chemotherapy. This innovative medication is already approved in Brazil and Mexico, showcasing its potential to greatly enhance patient care in these markets.
Reactions from Leadership
Samira Sakhia, the President and CEO of Knight Therapeutics, expressed enthusiasm about the partnership, stating that ONICIT® complements their existing oncology portfolio and enables them to improve patient outcomes in Latin America. She emphasizes the company’s commitment to expanding access to this vital treatment.
Commitment to Cancer Care
Dr. Melanie Rolli, CEO of Helsinn, echoed this sentiment, highlighting the company’s dedication to enhancing the quality of life for cancer patients. She remarked on Knight's favorable position and shared commitment to providing effective treatment options, which solidifies their ongoing partnership.
About ONICIT®: A Pharmacological Marvel
ONICIT® not only addresses acute nausea and vomiting but also prevents delayed symptoms that patients often experience after chemotherapy. This aspect is particularly important, as it can significantly impact a patient's quality of life during their treatment journey. Furthermore, ONICIT® has been indicated for postoperative nausea and vomiting, underscoring its versatility and importance in patient care.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. is focused on acquiring and commercializing specialized pharmaceutical products within Canada and Latin America. The company operates under several subsidiaries, enhancing its reach and efficacy in the pharmaceutical market. The stock of Knight Therapeutics Inc. is actively traded on the TSX under the symbol GUD.
About Helsinn Healthcare SA
Founded in 1976, Helsinn operates out of Lugano, Switzerland, and has established a long-standing reputation for improving patient quality of life through thoughtful pharmaceutical innovation. The company is deeply committed to oncology and supportive care, dedicated to sustainable growth which aligns with its core mission and values.
Frequently Asked Questions
What is the main aim of the agreement between Knight and Helsinn?
The agreement focuses on the exclusive distribution of ONICIT® in Latin America, allowing Knight to enhance access to this important treatment.
What are the benefits of using ONICIT®?
ONICIT® is effective in preventing both acute and delayed nausea and vomiting associated with chemotherapy, significantly improving patient comfort.
Where is ONICIT® approved for use?
ONICIT® is currently approved and marketed in Brazil and Mexico for the prevention of nausea and vomiting related to chemotherapy and surgery.
How does Knight Therapeutics Inc. support cancer patients?
Through its expanding portfolio and partnerships, Knight aims to provide innovative treatments that enhance the quality of life for cancer patients in Latin America.
What areas does Helsinn focus on as a pharmaceutical company?
Helsinn specializes in oncology and supportive care, striving to deliver high-quality patient care through its pharmaceutical developments.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
